Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Royalty Pharma plcRPRX · Entity 3100 | EVP, Investments & CLO | December 17, 2025 | December 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Royalty Pharma plc
Report date December 17, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy GWL 2014 G, LLC | 30,654 |
Reported balance
After 2025-12-17 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-12-17 · Sale · Disposed 79,346 · Balance 30,654 F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy GWL 2014 G, LLC | 0 |
Reported balance
After 2025-12-18 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-12-18 · Sale · Disposed 30,654 · Balance 0 F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy GWL 2013 NG, LLC | 495,860 |
Reported balance
Holding disclosure · report date 2025-12-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 495,860 |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy IRA | 273,960 |
Reported balance
Holding disclosure · report date 2025-12-17 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 273,960 |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy GWL 2023 G HoldCo LLC | 6,084 |
Reported balance
Holding disclosure · report date 2025-12-17 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 6,084 |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy Spouse | 4,011.19 |
Reported balance
Holding disclosure · report date 2025-12-17 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 4,011.19 |
Filing footnotes · ownership attribution and instrument terms
F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2021 Filed Nov 18, 2021 19:18 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 27,341 | $43.19 | $1,180,822.25 |
DisclosureSEC source: 0001209191-21-065639 · doc4.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 495,860 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.60 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 19:18 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 72,659 | $42.33 | $3,075,379.37 |
DisclosureSEC source: 0001209191-21-065639 · doc4.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 523,201 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.98 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2021 Filed Nov 18, 2021 19:18 UTC | Royalty Pharma plc RPRX · Entity 3100 | GiftLP interests in RPI US Partners 2019, LP · Derivative | 1,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065639 · doc4.xml · derivative · entry 9 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,889 Underlying: Class A Ordinary Shares · 12,820 shares Expires not disclosed F5 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange. F6 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold. F7 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F7 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F8 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 7,397,096 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. Read SEC document |
| July 26, 2021 Filed Jul 27, 2021 17:29 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 8,449 | $39.76 | $335,941.53 |
DisclosureSEC source: 0001209191-21-048317 · doc4.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 780,000 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.56 to $40.21 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 26, 2021 Filed Jul 27, 2021 17:29 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 4,913 | $39.81 | $195,590.95 |
DisclosureSEC source: 0001209191-21-048317 · doc4.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 595,860 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.57 to $40.21 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 17:18 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 17,981 | $42.01 | $755,362.03 |
DisclosureSEC source: 0000899243-21-028335 · doc4.xml · nonDerivative · entry 3 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 788,449 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 17:18 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 5,068 | $42.01 | $212,889.96 |
DisclosureSEC source: 0000899243-21-028335 · doc4.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 600,773 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 17:18 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 100 | $42.04 | $4,204.00 |
DisclosureSEC source: 0000899243-21-028335 · doc4.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 806,430 Read SEC document |
| July 08, 2021 Filed Jul 8, 2021 19:36 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 40,667 | $42.05 | $1,709,900.95 |
DisclosureSEC source: 0000950103-21-010244 · dp154126_4-lloyd.xml · nonDerivative · entry 6 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 806,530 F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.21 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 08, 2021 Filed Jul 8, 2021 19:36 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 8,392 | $42.05 | $352,887.80 |
DisclosureSEC source: 0000950103-21-010244 · dp154126_4-lloyd.xml · nonDerivative · entry 5 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 605,841 F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.21 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 19:36 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 2,500 | $42.01 | $105,022.00 |
DisclosureSEC source: 0000950103-21-010244 · dp154126_4-lloyd.xml · nonDerivative · entry 4 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 847,197 F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 19:36 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 400 | $42.02 | $16,806.00 |
DisclosureSEC source: 0000950103-21-010244 · dp154126_4-lloyd.xml · nonDerivative · entry 3 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 614,233 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.01 to $42.02 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 19:36 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 30,303 | $42.41 | $1,285,025.99 |
DisclosureSEC source: 0000950103-21-010244 · dp154126_4-lloyd.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 849,697 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.84 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 19:36 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 6,227 | $42.42 | $264,118.83 |
DisclosureSEC source: 0000950103-21-010244 · dp154126_4-lloyd.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 614,633 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.04 to $42.88 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 18:42 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 10,000 | $46.45 | $464,491.00 |
DisclosureSEC source: 0000950103-21-008761 · dp152652_4-lloyd.xml · nonDerivative · entry 3 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 240,000 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.40 to $46.65 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 18:42 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 40,000 | $46.52 | $1,860,772.00 |
DisclosureSEC source: 0000950103-21-008761 · dp152652_4-lloyd.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 880,000 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.40 to $46.69 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 18:42 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 20,000 | $46.46 | $929,106.00 |
DisclosureSEC source: 0000950103-21-008761 · dp152652_4-lloyd.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 620,860 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.40 to $46.66 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 08, 2021 Filed Jun 8, 2021 20:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 10,000 | $46.47 | $464,747.00 |
DisclosureSEC source: 0000950103-21-008571 · dp152452_4-lloyd.xml · nonDerivative · entry 12 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 250,000 F12 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.40 to $46.70 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 08, 2021 Filed Jun 8, 2021 20:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 40,000 | $46.48 | $1,859,344.00 |
DisclosureSEC source: 0000950103-21-008571 · dp152452_4-lloyd.xml · nonDerivative · entry 11 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 920,000 F11 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.40 to $46.69 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 08, 2021 Filed Jun 8, 2021 20:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 20,000 | $46.48 | $929,540.00 |
DisclosureSEC source: 0000950103-21-008571 · dp152452_4-lloyd.xml · nonDerivative · entry 10 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 640,860 F10 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.40 to $46.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 20:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 4,853 | $46.54 | $225,859.11 |
DisclosureSEC source: 0000950103-21-008571 · dp152452_4-lloyd.xml · nonDerivative · entry 9 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 260,000 F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.44 to $46.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 20:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 15,147 | $45.89 | $695,109.46 |
DisclosureSEC source: 0000950103-21-008571 · dp152452_4-lloyd.xml · nonDerivative · entry 8 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 264,853 F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.50 to $46.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 20:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 36,619 | $46.74 | $1,711,696.56 |
DisclosureSEC source: 0000950103-21-008571 · dp152452_4-lloyd.xml · nonDerivative · entry 7 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 960,000 F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.50 to $47.07 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 20:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 33,381 | $46.10 | $1,538,767.30 |
DisclosureSEC source: 0000950103-21-008571 · dp152452_4-lloyd.xml · nonDerivative · entry 6 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 996,619 F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.50 to $46.49 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 20:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 13,400 | $46.77 | $626,719.34 |
DisclosureSEC source: 0000950103-21-008571 · dp152452_4-lloyd.xml · nonDerivative · entry 5 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 660,860 F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.50 to $47.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 20:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 19,100 | $45.97 | $878,076.66 |
DisclosureSEC source: 0000950103-21-008571 · dp152452_4-lloyd.xml · nonDerivative · entry 4 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 674,260 F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.50 to $46.48 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 20,000 | $44.81 | $896,204.00 |
DisclosureSEC source: 0000950103-21-008571 · dp152452_4-lloyd.xml · nonDerivative · entry 3 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 280,000 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.72 to $44.89 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 20,000 | $44.85 | $897,028.00 |
DisclosureSEC source: 0000950103-21-008571 · dp152452_4-lloyd.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 1,030,000 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.53 to $45.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 20,000 | $44.69 | $893,706.00 |
DisclosureSEC source: 0000950103-21-008571 · dp152452_4-lloyd.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 693,360 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.15 to $45.04 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 18:48 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 50,000 | $42.13 | $2,106,385.00 |
DisclosureSEC source: 0000950103-21-008456 · dp152316_4-lloyd.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 1,050,000 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.56 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 18:48 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 12,500 | $42.09 | $526,127.50 |
DisclosureSEC source: 0000950103-21-008456 · dp152316_4-lloyd.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 713,360 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.26 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:05 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-007076 · dp150858_4-lloyd.xml · derivative · entry 8 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 264,027 Underlying: Class A Ordinary Shares · 300,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,090 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:05 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 90,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-007076 · dp150858_4-lloyd.xml · derivative · entry 7 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 172,680 Underlying: Class A Ordinary Shares · 900,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,090 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:05 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 67,586 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-007076 · dp150858_4-lloyd.xml · derivative · entry 6 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 675,860 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:05 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-007076 · dp150858_4-lloyd.xml · nonDerivative · entry 3 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 300,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,090 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:05 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 900,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-007076 · dp150858_4-lloyd.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 1,100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,090 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:05 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 675,860 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-007076 · dp150858_4-lloyd.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 725,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,090 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 17:57 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 55,898 | $42.14 | $2,355,485.82 |
DisclosureSEC source: 0000950103-21-005664 · dp149489_4-lloyd.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 200,000 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.41 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 17:57 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 13,924 | $42.12 | $586,434.32 |
DisclosureSEC source: 0000950103-21-005664 · dp149489_4-lloyd.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 50,000 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.40 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 07:52 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 360 | $42.32 | $15,235.20 |
DisclosureSEC source: 0000950103-21-005530 · dp149384_4-lloyd.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 255,898 Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 07:52 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 89 | $42.32 | $3,766.48 |
DisclosureSEC source: 0000950103-21-005530 · dp149384_4-lloyd.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 63,924 Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 17:25 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 100 | $47.04 | $4,704.00 |
DisclosureSEC source: 0000950103-21-004521 · dp147364_4-lloyd.xml · nonDerivative · entry 3 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 256,258 Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 17:25 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 43,642 | $46.32 | $2,021,436.34 |
DisclosureSEC source: 0000950103-21-004521 · dp147364_4-lloyd.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 256,358 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.025 to $47.01 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 17:25 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 10,987 | $46.34 | $509,085.94 |
DisclosureSEC source: 0000950103-21-004521 · dp147364_4-lloyd.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 64,013 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.04 to $46.98 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 19:03 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 3,510 | $47.85 | $167,947.88 |
DisclosureSEC source: 0000950103-21-003570 · dp147384_4-lloyd.xml · nonDerivative · entry 4 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 300,000 F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.56 to $48.05 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 19:03 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 96,490 | $46.89 | $4,524,367.86 |
DisclosureSEC source: 0000950103-21-003570 · dp147384_4-lloyd.xml · nonDerivative · entry 3 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 303,510 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.56 to $47.55 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 19:03 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 2,625 | $47.84 | $125,574.75 |
DisclosureSEC source: 0000950103-21-003570 · dp147384_4-lloyd.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 75,000 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.55 to $48.05 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 19:03 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 22,375 | $46.89 | $1,049,257.73 |
DisclosureSEC source: 0000950103-21-003570 · dp147384_4-lloyd.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 77,625 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.54 to $47.50 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:43 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 40,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-000104 · dp143909_4-lloyd.xml · derivative · entry 6 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 556,707 Underlying: Class A Ordinary Shares · 400,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F2 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F4 · balance_after: Includes RPI US LP Interests convertible into 4,573,096 Class A Ordinary Shares that are subject to an agreement by and between the reporting person and RP Management, LLC under which the reporting person has agreed to retain and not sell such interests before February 2025. This restriction is waivable under certain circumstances. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:43 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-000104 · dp143909_4-lloyd.xml · derivative · entry 5 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 73,638 Underlying: Class A Ordinary Shares · 100,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F2 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F3 · balance_after: Includes RPI US LP Interests convertible into 60,520 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.